Cargando…
P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
Autores principales: | Oertel, Michael, Hering, Dominik, Nacke, Nina, Kittel, Christopher, Kröger, Kai, Kriz, Jan, Fuchs, Michael, Baues, Christian, Vordermark, Dirk, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Marnitz, Simone, Borchmann, Peter, Engert, Andreas, Haverkamp, Uwe, Eich, Hans Theodor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621491/ http://dx.doi.org/10.1097/01.HS9.0000890936.73031.da |
Ejemplares similares
-
P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
por: Oertel, Michael, et al.
Publicado: (2022) -
P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
por: Oertel, Michael, et al.
Publicado: (2022) -
Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma– a risk stratified analysis of the GHSG HD17 trial
por: Oertel, Michael, et al.
Publicado: (2023) -
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era
por: Oertel, Michael, et al.
Publicado: (2022) -
Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients – An Analysis of GHSG HD14- and HD17-Patients
por: Rosenbrock, Johannes, et al.
Publicado: (2021)